1. Method development and validation study for quantitative determination of 2-chloromethyl-3,4-dimethoxy pyridine hydrochloride a genotoxic impurity in pantoprazole active pharmaceutical ingredient (API) by LC/MS/MS;Venugopal;J. Pharm. Biomed. Anal.,2012
2. EMEA, Safety Working Group. Questions and Answers on the Guideline on the Limits of Genotoxic Impurities, EMEA, London, 2010, CHMP/SWP/431994/2007 Rev. September 3 2010.
3. EMEA, Committee for Medicinal Products (CHMP). Guideline on the Limits of Genotoxic Impurities, EMEA, London, 2006, CPMP/SWP/5199/02, June 28 2006.
4. USFDA, Guidelines for industry; Genotoxic and carcinogenic impurities in drug substances and products: recommended approaches (draft), December 2008.
5. ICH M7. Guideline on Assessment and Control of DNA Reactive (Mutagenic) Impurities in Pharmaceuticals to Limit Potential Carcinogenic Risk, June 2014.